Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 10, 2017All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor
NEWTON, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has received written notice from the...
-
Mar 9, 2017
NEWTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year...
-
Mar 2, 2017Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain on Study
NEWTON, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the results of a planned interim analysis of...
-
Mar 1, 2017Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study)
NEWTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 12 abstracts describing the Company's...
-
Jan 31, 2017
NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Jan 3, 2017
NEWTON, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Dec 15, 2016- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS -
NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Target ALS Foundation, a non-profit...
-
Dec 5, 2016- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide -
NEWTON, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 1b...
-
Dec 4, 2016- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 2 SAIL study,...
-
Dec 4, 2016- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from its Phase 2b STORM study...